ROIV Company Profile and Key Details

ROIV has shown sold momentum, gaining 3.7% over the past week and 33.14% over the past quarter, though year-to-date performance is up 5.9%. Short-term trend indicators are bearishly aligned (SMA20 10.94%, SMA50 20.18%, SMA200 69.97%). The stock’s 14-day RSI is 71.86 (overbought), while the ATR of 0.97 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -2.43% below its high and over 226.35% above its low. Average 10-day trading volume of 9.69 million shares is significantly above the 3-month average of 6.13 million, indicating heightened recent market interest.

Roivant Sciences Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.85. This means the shares are trading above this model’s fair value.

Roivant Sciences Ltd. (NASDAQ:ROIV) closed at $34.93 USD, gaining $0.52 (1.51%) from the previous close of $34.41. The stock is currently mid-range between its 52-week high and low $12.54 and $37.97. With a market capitalization of about $25.23 billion, Roivant Sciences Ltd. is classified as a large-cap and shows market-like volatility (beta ~1.13). Key stats such as the average daily volume over the past year has been around 6.24 million shares, in line with its 52-week average. Headquartered in London, GL, Roivant Sciences Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Matthew Gline, the company employs approximately 721 people and listed since December 08, 2020. Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs.

Roivant Sciences Ltd. generated EPS of -$1.17 over the past year. Five-year average earnings growth is -99.51%. The latest quarter delivered EPS of -$0.33. The next quarter is forecast at -$0.31. Next year's EPS is expected at $15.86. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 16 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $42.00 to $16.50. The high target offers 20.24% upside. The low target suggests -52.76% downside. The mean target is $29.07. This offers -16.78% upside. Roivant Sciences Ltd. earnings surprise history is frequent misses against expectations. The quarter that ended August 06, 2026, missed forecasts by 2.45%. The prior quarter beat by -3.22%. Over the last six quarters, Apple has recorded several small beats. These include -16.51% in May 29, 2025.

Roivant Sciences Ltd. has 722.32 million shares outstanding. The public float is 580.44 million shares, elevated short interest at 6.42% of float. This equals 35.23 million shares. The short ratio is 7.46 days. Institutional investors hold 99.8% of the float. Insiders own 21.45%. Dexcel Pharma Technologies Ltd. holds 102.85 million shares, SVF Investments (UK) Ltd has 73.03 million shares and Sumitomo Chemical Co., Ltd. has 71.25 million shares. Over the past six months, insider transactions show net selling. They sold 6.20 million shares across 29 transactions.

Roivant Sciences Ltd. trades at a P/E ratio of -92.04, slightly below the S&P 500 average, with a price-to-sales ratio of 3354.36 and a price-to-book ratio of 5.96 trading at moderately above to book value. The P/FCF stands at -31.04, also below market averages.

Our AI price prediction model suggests that Roivant Sciences Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.73%, with price expected at $32.93 by September 17, 2026, within a range of $31.83 to $33.88 3-Month Outlook: Projected fall of -16.49%, reaching $29.17 by December 02, 2026, with a range of $27.83 to $30.31. 1-Year Outlook: Projected gain of 17.81%, with price at $41.15 by September 03, 2027, within a range of $39.34 to $42.70.

Roivant Sciences Ltd. (NASDAQ:ROIV) shares are flat 5.9% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Roivant Sciences Ltd. trading at a premium to the broader market with a P/E of -92.04. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $20.22, suggesting -42.11% downside. Our AI forecast model points to short-term weakness (-5.73% over two weeks), a medium-term fall (-16.49% over three months), and a longer-term gain (17.81% over one year), with expected trading ranges indicating moderate volatility.